Comparative Pharmacology
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus NATURETIN 2 5.
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus NATURETIN 2 5.
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE vs NATURETIN-2.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosinopril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
1 tablet (fosinopril 10 mg/hydrochlorothiazide 12.5 mg or fosinopril 20 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: fosinopril 80 mg/hydrochlorothiazide 50 mg per day.
Hypertension: 2.5 mg orally once daily; may increase to 5 mg daily if needed. Edema: 2.5 to 10 mg orally once daily.
None Documented
None Documented
Fosinoprilat: 11.5 h (terminal); Hydrochlorothiazide: 6-15 h (biphasic, terminal phase 10-15 h).
Terminal elimination half-life: 6-9 hours; prolonged in renal impairment and in elderly patients.
Fosinopril: 45% renal, 55% biliary/fecal; Hydrochlorothiazide: >95% renal (unchanged).
Renal excretion: approximately 95% as unchanged drug; biliary/fecal: <5%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic